Eli Lilly (LLY) Q1 FY26 earnings call

Eli Lilly delivered robust Q1 FY26 results, driven by strong incretin performance and the successful launch of Foundayo for obesity. The company advanced its pipeline with multiple positive Phase III readouts and initiated new programs, while strategically expanding through business development. Management remains confident in its ability to sustain industry-leading growth, focusing on patient access and market expansion for its key therapeutic areas.